TY1A-GR1 Antibody

What is the Ly-6G/Gr-1 antigen and why is it important in immunological research?

Ly-6G/Gr-1 is a myeloid differentiation antigen that belongs to the Ly-6 family of glycosylphosphatidylinositol (GPI)-anchored proteins. It is predominantly expressed on granulocytes in bone marrow and is a 21-25 kDa protein. The importance of this marker lies in its specific expression pattern, making it valuable for identifying and targeting neutrophils in research studies. Ly-6G is extensively used as a neutrophil marker in murine models of inflammation, infection, and tissue injury . Its targeted depletion using antibodies has become a standard approach to investigate neutrophil functions in various disease contexts.

What is the difference between the RB6-8C5 and 1A8 anti-Ly-6G antibody clones?

The RB6-8C5 and 1A8 clones represent two different antibodies targeting the Ly-6G antigen, but with important specificity differences:

• RB6-8C5 clone: Binds to the myeloid differentiation antigen Gr-1, which encompasses both Ly-6G and Ly-6C. While it effectively targets neutrophils, it also shows reactivity with Ly-6C-expressing cells, including subpopulations of monocytes and lymphocytes .

• 1A8 clone: Binds specifically to Ly-6G with minimal cross-reactivity. Unlike RB6-8C5, the 1A8 antibody does not react significantly with Ly-6C-transfected cells, making it more neutrophil-specific .

This distinction is crucial when designing experiments requiring selective neutrophil depletion without affecting other leukocyte populations.

How does anti-Ly-6G/Gr-1 antibody treatment affect neutrophil populations in vivo?

Administration of anti-Ly-6G/Gr-1 antibody (clone RB6-8C5) effectively depletes circulating neutrophils in mice. In spinal cord injury models, treatment with 4 mg/kg intraperitoneal injections at 2 and 24 hours post-injury reduced neutrophil numbers by >90% compared to controls treated with isotype-matched antibodies . Complete blood counts showed that neutrophil levels typically peak 6-12 hours after injury with approximately 3-fold increase over uninjured controls, and anti-Ly-6G/Gr-1 treatment drastically reduces these elevated levels .

The depletion mechanism involves antibody-mediated clearance of neutrophils primarily through the reticuloendothelial system. This reduces both circulating neutrophils and their infiltration into injured tissues, as confirmed by flow cytometry and immunohistochemical analyses .

What are the optimal protocols for neutrophil depletion using anti-Ly-6G/Gr-1 antibodies?

Based on established research protocols, the following approaches have demonstrated efficacy:

Standard Protocol:

• Antibody Selection: Functional grade purified anti-mouse Ly6G/Gr-1 (clone RB6-8C5) or isotype-matched control antibodies (IgG2b isotype control)

• Dosage: 4 mg/kg body weight

• Administration: Intraperitoneal injection

• Timing: Initial administration at 2 hours post-injury/intervention, followed by a second dose at 24 hours

• Verification: Complete blood counts and flow cytometry analysis using CD45 and CD11b markers to confirm depletion efficacy

For researchers requiring more specific neutrophil targeting with minimal effects on other cell populations, the 1A8 clone is recommended, though specific dosing may differ from the RB6-8C5 protocol.

How should flow cytometry be designed to accurately assess neutrophil depletion efficiency?

For optimal assessment of neutrophil depletion efficiency, the following flow cytometry approach is recommended:

Sample Preparation:

• Collect peripheral blood samples at multiple timepoints (baseline, 6h, 12h, 24h, 48h post-treatment)

• Prepare single-cell suspensions from relevant tissues (spinal cord, bone marrow, or other target tissues)

Staining Panel:

• CD45 (leukocyte common antigen) - to identify all leukocytes

• CD11b - for myeloid cell identification

• Gr-1 (Ly-6G) - for neutrophil identification

• Additional markers to exclude other cell populations: F4/80 (macrophages), CD107b (monocytes), CD3 (T lymphocytes)

Analysis Strategy:

• Generate density plots with CD45 on the y-axis and CD11b or Gr-1 on the x-axis

• Identify neutrophils as CD45high:Gr-1high population

• Confirm neutrophil identity by verifying they are negative for F4/80, CD107b, and CD3

• Calculate depletion efficiency by comparing neutrophil percentages between treated and control groups

What controls should be included when using anti-Ly-6G/Gr-1 antibodies in depletion studies?

Comprehensive experimental design for neutrophil depletion studies should include these essential controls:

• Isotype Control Antibody: Animals receiving IgG2b isotype-matched control antibodies at identical dosage and timing as the experimental group to control for non-specific antibody effects

• Untreated Injured Group: Animals subjected to the same injury or stimulus but receiving no antibody treatment to establish baseline inflammatory responses

• Sham/Uninjured Control: Animals undergoing sham procedures without injury to establish baseline neutrophil levels

• Time Course Controls: Multiple timepoint sampling to track the duration of depletion effect

• Cell Specificity Controls: Flow cytometry analysis incorporating markers for other leukocyte populations (monocytes, lymphocytes) to confirm selective neutrophil depletion

• Dose-Response Controls: If performing pilot studies, include different antibody dosages to establish optimal depletion protocols

This control scheme allows researchers to distinguish between effects caused by neutrophil depletion versus non-specific antibody effects or natural injury progression .

How should researchers interpret unexpected results where anti-Ly-6G/Gr-1 treatment worsens outcomes?

When anti-Ly-6G/Gr-1 treatment produces unexpected negative outcomes, as observed in spinal cord injury models, several interpretive frameworks should be considered:

Protective Neutrophil Functions: Neutrophils may play beneficial roles in certain contexts through:

• Production of growth factors and chemokines that promote wound healing

• Initial inflammatory responses that mobilize other beneficial immune cells

• Clearance of cellular debris that could otherwise exacerbate tissue damage

In spinal cord injury studies, anti-Ly-6G/Gr-1 treatment resulted in reduced astrocyte reactivity, decreased white matter sparing, and diminished axonal preservation compared to controls. These histological outcomes correlated with worse behavioral recovery as measured by the Basso Mouse Scale .

Methodological Considerations:

• Confirm antibody specificity and depletion efficiency through flow cytometry

• Examine the timing of depletion relative to the natural injury progression

• Consider whether compensatory immune mechanisms are activated when neutrophils are depleted

• Investigate cell-specific effects by correlating neutrophil numbers in target tissues with outcome measures

These unexpected results highlight the complex and potentially beneficial roles neutrophils may play in certain injury contexts, challenging the assumption that neutrophil-mediated inflammation is universally detrimental .

How can researchers determine if anti-Ly-6G/Gr-1 antibody affects cell populations other than neutrophils?

To determine potential off-target effects of anti-Ly-6G/Gr-1 antibody, implement the following comprehensive assessment:

Flow Cytometry Analysis:

• Design multi-parameter panels that include markers for:

  • Neutrophils (CD45high, Gr-1high)

  • Monocytes (CD45high, CD11b+, F4/80+, CD107b+)

  • Lymphocytes (CD45+, CD3+)

  • Resident microglia in CNS studies (CD45low, CD11b+)

• Compare population percentages between anti-Ly-6G/Gr-1 and isotype control groups

Complete Blood Counts:

• Perform differential counts to quantify changes in all major leukocyte populations

• Track kinetics of cell population changes at multiple timepoints

Tissue Immunohistochemistry:

• Use antibody combinations targeting:

  • Microglia/macrophages (Iba-1)

  • Neutrophils (clone 7/4)

  • Other relevant cell types depending on tissue context

• Quantify cell numbers and activation states in tissue sections

In studies using the RB6-8C5 clone, researchers have noted that while this antibody may have affinity for Ly6C expressed on subpopulations of monocytes and lymphocytes, the treatment typically reduces neutrophil numbers by >90% without obvious alteration of monocyte or lymphocyte numbers in most experimental contexts .

What factors can influence the efficiency of neutrophil depletion using anti-Ly-6G/Gr-1 antibodies?

Multiple factors can impact neutrophil depletion efficiency:

Antibody-Related Factors:

• Clone selection: RB6-8C5 vs. 1A8 (specificity differences)

• Antibody quality and storage conditions

• Dosage and administration route

• Timing relative to neutrophil mobilization

Physiological Factors:

• Severity of inflammatory stimulus or injury

• Rate of neutrophil production in bone marrow

• Emergency myelopoiesis triggered by severe inflammation

• Antibody clearance rates in different disease states

Experimental Design Factors:

• Verification methodology (flow cytometry parameters, gating strategies)

• Sampling timepoints relative to antibody administration

• Target tissue accessibility to antibody

To optimize depletion efficiency, researchers should:

• Perform dose-finding pilot studies

• Implement rigorous verification of depletion using flow cytometry

• Consider repeated antibody administration for sustained depletion

• Account for disease-specific changes in neutrophil kinetics

How do neutrophil depletion outcomes differ across various disease models when using anti-Ly-6G/Gr-1 antibodies?

Neutrophil depletion using anti-Ly-6G/Gr-1 antibodies produces context-dependent outcomes across different disease models:

Central Nervous System Injury Models:

• In spinal cord injury, neutrophil depletion worsens functional recovery and reduces tissue preservation, suggesting a protective role for early neutrophil responses

• Depletion reduces astrocyte reactivity and may impair wound healing responses critical for CNS repair

Infection Models:

• Typically results in increased pathogen burden and worsened outcomes in bacterial infection models

• May improve outcomes in certain viral infections where neutrophil-mediated immunopathology dominates

Sterile Inflammation Models:

• Variable outcomes depending on tissue type and inflammatory stimulus

• May improve outcomes in models where neutrophil extracellular traps (NETs) drive pathology

Autoimmune Disease Models:

• Generally beneficial in antibody-mediated autoimmune conditions

• Variable effects in T-cell-mediated autoimmunity

These differential outcomes highlight the diverse roles neutrophils play across biological contexts and underscore the importance of pilot depletion studies in each new disease model.

What are the molecular mechanisms through which neutrophils might promote tissue healing after injury?

Recent research suggests several mechanisms by which neutrophils can promote tissue healing:

Growth Factor and Cytokine Production:

• Neutrophils produce various growth factors that promote wound healing

• They secrete chemokines that recruit reparative immune cell populations

• The timing and context of neutrophil infiltration can determine whether pro-inflammatory or pro-resolving factors predominate

Cellular Debris Clearance:

• Efficient phagocytosis of cellular debris prevents secondary necrosis

• Neutrophil apoptosis and subsequent clearance by macrophages triggers anti-inflammatory pathways

Tissue Remodeling:

• Neutrophil-derived proteases contribute to extracellular matrix remodeling

• Neutrophils may influence fibronectin deposition and other aspects of the wound healing response

Vascular Functions:

• Neutrophils interact with endothelial cells to regulate vascular permeability

• They contribute to angiogenesis through release of specific factors

In spinal cord injury models, neutrophil depletion led to alterations in growth factors and chemokines important for promoting wound healing, suggesting these cells play complex roles beyond simple inflammatory damage .

How can researchers distinguish between direct effects of anti-Ly-6G/Gr-1 antibody treatment and secondary effects due to neutrophil depletion?

Distinguishing direct antibody effects from neutrophil depletion effects requires methodological sophistication:

Complementary Depletion Approaches:

• Compare anti-Ly-6G/Gr-1 antibody depletion with alternative neutrophil depletion methods

• Use multiple antibody clones (RB6-8C5 vs. 1A8) with different cross-reactivity profiles

• Consider genetic models of neutrophil deficiency as comparators

Reconstitution Experiments:

• Deplete neutrophils with antibody then reconstitute with adoptively transferred neutrophils

• If phenotypes reverse with neutrophil reconstitution, effects can be attributed to neutrophil absence

Temporal Analysis:

• Track the correlation between neutrophil numbers and phenotypic changes over time

• Determine if effects precede significant neutrophil depletion

In Vitro Controls:

• Test direct effects of antibody on relevant non-neutrophil cell types in culture

• Examine whether antibody-opsonized neutrophils produce different effects than simple neutrophil absence

Molecular Profiling:

• Perform transcriptomic or proteomic analysis of relevant tissues with both antibody types

• Identify changes specific to neutrophil absence versus potential direct antibody effects

These approaches collectively can help researchers attribute observed phenotypes correctly to neutrophil depletion rather than direct antibody effects .

What are emerging alternatives to anti-Ly-6G/Gr-1 antibodies for studying neutrophil functions?

The field is advancing with several promising alternatives to traditional antibody-mediated depletion:

Genetic Approaches:

• Inducible neutrophil-specific depletion models using diphtheria toxin receptor systems

• CRISPR/Cas9-mediated targeting of neutrophil-specific genes

• Conditional knockout systems targeting essential neutrophil survival factors

Small Molecule Inhibitors:

• Selective inhibitors of neutrophil recruitment (CXCR2 antagonists)

• Compounds targeting neutrophil-specific functions rather than depleting cells

• Inhibitors of neutrophil extracellular trap (NET) formation

Precision Neutrophil Manipulation:

• Antibodies targeting specific neutrophil activation states

• Approaches to modify neutrophil phenotypes rather than depleting them

• Engineered nanobodies with enhanced specificity for neutrophil subsets

These emerging approaches may overcome limitations of traditional antibody depletion, including incomplete depletion, potential off-target effects, and compensatory responses that can confound interpretation.

How might single-cell technologies enhance our understanding of neutrophil heterogeneity and depletion effects?

Single-cell technologies offer unprecedented opportunities to refine neutrophil research:

Single-Cell RNA Sequencing Applications:

• Identification of neutrophil subpopulations with distinct functions

• Characterization of cells that escape antibody-mediated depletion

• Comparative analysis of neutrophils across tissues and disease states

• Tracking of neutrophil states during injury and resolution phases

Mass Cytometry/CyTOF:

• High-dimensional phenotyping to identify neutrophil activation states

• Correlation of surface marker profiles with functional attributes

• Detection of rare neutrophil subsets that may have specialized functions

Spatial Transcriptomics:

• Analysis of neutrophil gene expression in tissue context

• Understanding spatial relationships between neutrophils and other cells

• Mapping of neutrophil functions to specific anatomical niches

These technologies could revolutionize our understanding of which neutrophil subsets are depleted by anti-Ly-6G/Gr-1 antibodies and whether certain functional subpopulations are more resistant to depletion or particularly important in tissue repair processes.